SCHEMBL3016473

SCHEMBL3016473

CCCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.43
HSD11B1 P28845 1/20 0.40
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GBA1 P04062 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019973 0.92 THRB (0.47) CNR1HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3007842 0.92 MEN1 (0.44) HSD11B1ALDH1A1GBA1MEN1LMNA
SCHEMBL3008698 0.91 POLB (0.46) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3010490 0.91 POLB (0.44) CNR1ALDH1A1SMN1; SMN2L3MBTL1GBA1
SCHEMBL3018162 0.90 ALDH1A1 (0.42) CNR1HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3009148 0.89 THRB (0.47) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3022474 0.89 MEN1 (0.44) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3013183 0.88 CNR1 (0.51) CNR1ALDH1A1SMN1; SMN2L3MBTL1GBA1
SCHEMBL3011226 0.88 TDP1 (0.49) ALDH1A1SMN1; SMN2L3MBTL1GBA1MEN1
SCHEMBL3007845 0.88 ALDH1A1 (0.43) CNR1ALDH1A1SMN1; SMN2L3MBTL1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CNR1 3069/4885HSD11B1 1034/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.